Royal Bank Of Canada Athenex, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.12 - $0.21 $93 - $164	-781 Reduced 47.51%	863 $0
Q3 2022 Nov 14, 2022	SELL	$0.24 - $1.11 $2,246 - $10,388	-9,359 Reduced 85.06%	1,644 $0
Q2 2022 Aug 15, 2022	SELL	$0.41 - $0.91 $3,603 - $7,997	-8,789 Reduced 44.41%	11,003 $5,000
Q1 2022 May 16, 2022	SELL	$0.79 - $1.59 $10,163 - $20,455	-12,865 Reduced 39.39%	19,792 $16,000
Q4 2021 Feb 14, 2022	BUY	$1.36 - $2.94 $9,623 - $20,803	7,076 Added 27.66%	32,657 $44,000
Q3 2021 Nov 15, 2021	SELL	$2.97 - $4.84 $267,451 - $435,846	-90,051 Reduced 77.88%	25,581 $78,000
Q2 2021 Aug 16, 2021	BUY	$3.71 - $5.13 $428,994 - $593,192	115,632 New	115,632 $535,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.